We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Generic firm Mylan Laboratories has filed a lawsuit against rival Watson Pharmaceuticals and brand firm Procter & Gamble (P&G) over an agreement that lets Watson market an authorized generic version of P&G’s urinary tract infection treatment during Mylan’s 180-day marketing exclusivity period for the product.
Four generic firms have won a patent challenge in the U.K. to market versions of GlaxoSmithKline’s (GSK’s) top-selling asthma drug Seretide (fluticasone propionate; salmeterol xinafoate).
In a defeat for Apotex, a federal judge has upheld a patent on Abbott Laboratories’ profitable treatment for epilepsy and mania associated with bipolar disorder.
Generic firms seeking to market a version of King Pharmaceuticals’ muscle relaxant Skelaxin (metaxalone) are not required to list some prescribing information on the product’s label, said the FDA in a decision that clears a roadblock to generic competition.
Aventis has filed additional patent infringement claims against five generic firms challenging the drugmaker’s top-selling Allegra allergy franchise — a move that will likely delay the start of trials by at least seven months.
Apotex has suffered a significant court defeat, with a federal judge’s ruling that its generic version of Abbott Laboratories’ treatment for epilepsy and mania associated with bipolar disorder infringes on the drugmaker’s patent.
A federal judge has ruled that Apotex’s generic version of Abbott Laboratories’ treatment for epilepsy and mania associated with bipolar disorder infringes on the drugmaker’s patent.
Generic firms should stop cutting deals with brand firms to market authorized versions of their products because the practice could devalue the 180-day exclusivity provision in the federal drug patent law, according to the Generic Pharmaceutical Association (GPhA).